Time to TEAM: Exemestane, or tamoxifen then exemestane?

The Lancet

Volumn 377, Issue 9762, 2011, Pages 280-281

  Coombes, R Charles ^a   Kilburn, Lucy S ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CANCER; DISEASE FREE SURVIVAL; EARLY CANCER; FOLLOW UP; FRACTURE; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MONOTHERAPY; NOTE; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 78751676229     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60073-1     Document Type: Note

References (10)

1. CJH Van de Velde, D Rea, C Seynaeve Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial Lancet 377 2011 321 331
2. RC Coombes, E Hall, LJ Gibson for the Intergroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092 (Pubitemid 38298988)
3. The BIG 1-98 Collaborative Group Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
4. AS Coates, A Keshaviah, B Thürlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492
5. J Cuzick, I Sestak, M Baum on behalf of the ATAC/LATTE investigators Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 2010 1135 1141
6. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
7. RC Coombes, LS Kilburn, CF Snowdon on behalf of the Intergroup Exemestane Study Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
8. M Dowsett, J Cuzick, J Ingle Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518
9. SE Jones, C Seynaeve, A Hasenburg Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 10-14, 2008: 15 (abstr) http://www.sabcs.org/EnduringMaterials/index.aspslidereview (accessed Dec 28, 2010).
10. JMS Bartlett, CL Brookes, LJ Billingham A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen. 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 10-14, 2008: 81 (abstr) http://www.sabcs.org/Newsletter/Docs/SABCS- 2008-Issue1.pdf (accessed Jan 16, 2011).